Enabling the arrival of advanced therapies from pre-clinical stages to industrial production and clinical application: this is the objective of ADVANCECAT project, led by the University of Barcelona (UB) and Ferrer, and build up by eighteen entities of the health field in which there are two universities, twelve biomedical research institutes or private foundations, and four companies.
ADVANCECAT, integrated in the NEXTHEALTH community, coordinated by Biocat, aims to create an organizational structure to speed up the development of new drugs for advanced therapies, grouping public and private actors of the field for a better resource management in order to get the maximum benefit in the Catalan health system. The main core of work is focused on promoting cell therapies and tissue engineering, strengthen genic therapy approaches, including immunotherapy, and developing production automatisms to get a better clinical application.
The project aims to reinforce the Catalan industrial sector by promoting the identification of mechanisms and protocols that allow industrial production of these drugs. Promoting interaction between research centers and hospitals and committed business tissue in these kinds of therapies will encourage the fast transition of the new drugs in the health system, which would however need long periods of development in lots of cases.
New research sheds light on how GLP-1 obesity drugs may change food cravings